22 results about "Stromal tumor" patented technology

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.

The invention relates to a YLPM1 protein and application of an accelerant of the YLPM1 protein. Specifically, the invention provides application of the YLPM1 protein and an accelerant thereof in preparation of a preparation or a pharmaceutical composition, and the preparation or the pharmaceutical composition is used for inhibiting growth and metastasis of gastrointestinal stromal tumor cells and promoting apoptosis of the gastrointestinal stromal tumor cells. The invention also provides application of the YLPM1 detection reagent and the YLPM1 knockout reagent, and a method for screening a potential therapeutic agent for treating gastrointestinal stromal tumor.

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and / or solvates of any of the foregoing which are useful for treating diseases and conditions related to mutant KIT and PDGFRa and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRa. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

This invention relates to the crystal form of Bezuclastinib and its preparation method, pharmaceutical compositions containing the crystal form, and the use of the crystal form in the preparation of drugs that inhibit KIT D816V mutations and drugs for treating gastrointestinal stromal tumors and progressive systemic mastocytosis.

This article provides a method for treating individuals with KIT-positive cancers such as gastrointestinal stromal tumors (GIST) and melanomas, wherein the method involves administering a menin inhibitor, optionally in combination with a KIT inhibitor, to the individual.

The invention relates to the technical field of image data processing, in particular to a CT image feature extraction method for gastrointestinal stromal tumor risk stratification, which comprises the following steps of: firstly, acquiring an abdominal CT plane scanning period image and a venous period image of a gastrointestinal stromal tumor patient, and performing coarse segmentation by utilizing gray scale difference of the two periods to obtain a tumor suspected area; a suspected content area is identified by analyzing gray change characteristics of the edge of the area, whether the suspected content area is a real gastrointestinal tract content (such as a contrast agent or bubbles) is further verified, the confirmed content is removed, a pure gastrointestinal stromal tumor area is finally obtained, and radiomics characteristics for risk stratification are extracted from the pure gastrointestinal stromal tumor area. According to the scheme, interference of gastrointestinal tract contents on tumor boundary judgment and internal texture analysis is effectively eliminated, so that the segmentation result is more accurate, high-quality data is provided for image omics feature extraction, the accuracy and reliability of risk layering are enhanced, and preoperative noninvasive accurate evaluation is realized.

The invention relates to a capture probe group, a kit and a detection method for detecting genetic susceptibility related gene variation of gastrointestinal stromal tumor. The kit comprises a capture probe group for detecting gastrointestinal stromal tumor genetic susceptibility related gene variation conditions and a corresponding reagent based on a next-generation sequencing technology. On the basis of a next-generation sequencing technology, variation conditions of genetic susceptibility related genes NF1, SDHA, SDHB, SDHC and SDHD of the gastrointestinal stromal tumor can be detected at one time by utilizing a hybrid capture method. The capture probe used in the invention has wide coverage and high sequencing depth, and can detect the embryonic line variation of all exon regions of the designed gene. A variant gene library is obtained according to a capture probe, gene variation sites are obtained through sequencing and comparison to a reference genome, all related diseases of gastrointestinal stromal tumor genetic susceptibility related genes can be reported according to databases such as existing literatures and guidelines, pathogenicity of variation and the like, and genetic modes corresponding to the diseases are provided.

The present invention provides a compound of Formula I, a salt thereof, or a solvate thereof, as described herein, the composition is used for treating MYC positive cancers including lung cancer, leukemia, breast cancer, myeloproliferative diseases, colorectal cancer, medulloblastoma, kidney cancer, hepatocellular cancer, melanoma, ovarian cancer, prostate cancer, esophageal adenocarcinoma, liposarcoma, esophageal squamous carcinoma, gastrointestinal stromal tumor, glioma, mucus fibrosarcoma, smooth muscle sarcoma, neuroblastoma, synovial sarcoma, mesothelioma, and the like. Gastric cancer, thyroid cancer, lymphoma, osteosarcoma, rhabdomyosarcoma, fibrosarcoma, epithelial cancer and neurological cancer.

The application provides a gastrointestinal stromal tumor patient diagnosis and treatment method and device based on multiple agents, the method comprising: acquiring multi-modal patient data, and acquiring a multi-modal base model based on the multi-modal patient data; performing supervised fine-tuning on the multi-modal base model, and performing reinforcement alignment using a preset group relative strategy optimization algorithm to obtain a multi-modal base model after two-stage reasoning capability training; and generating a standardized reasoning result based on the trained multi-modal base model. According to the application, the perceived multi-modal base model is trained for two-stage reasoning capability, and the multi-modal base model is used to generate a reasoning result, so that the perception task is no longer isolated, and perception, reasoning and tracking diagnosis and treatment are integrated into a unified process. In addition, longitudinal decision training is realized, the comprehensiveness of decision training is improved, and the accuracy of reasoning is improved.

The application belongs to the field of medicine, and particularly relates to a novel quinoline compound containing 6-oxo-1-substituted phenyl-1,6-dihydropyridazine-3-carboxamide and application thereof. The novel quinoline compound containing 6-oxo-1-substituted phenyl-1,6-dihydropyridazine-3-carboxamide has a structure of general formula (I). The application also relates to the compound of general formula (I) having a strong inhibitory effect on c-Met kinase, and further relates to the use of the compound and a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and / or preventing a disease caused by abnormally high expression of c-Met kinase, in particular, in the preparation of a drug for treating and / or preventing cancer. The compound of the application is particularly suitable for preparing a drug for treating and / or preventing gastric cancer, colon cancer, lung cancer, gastrointestinal stromal tumor and imatinib-resistant human gastrointestinal stromal tumor.

The present disclosure provides compounds of Formula I, pharmaceutical salts thereof, and / or solvates of any of the foregoing, which are useful for treating diseases and conditions related to mutant KIT and PDGFRα and present an advantageously non-brain penetrant profile for treating diseases and conditions related to mutant KIT and PDGFRα. The present disclosure also provides methods for treating gastrointestinal stromal tumors and systemic mastocytosis.

Disclosed are compounds, methods, compositions, uses, and kits that allow for treating cancer. In some embodiments, the compounds are used to treat diseases or disorders. The compounds may treat cancer by targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, lymphoma, liver cancer, endometrial cancer, leukemia, or multiple myeloma. Disclosed are compounds, methods, compositions, uses, and kits that may be used in regenerative medicine. The compounds utilized in the disclosure are of Formula (0) and (I).

The invention relates to the technical field of tumor treatment, in particular to a VEGFR-2 / BRD4 double-target inhibitor and application thereof. The structural general formula of the VEGFR-2 / BRD4 double-target inhibitor is as shown in a formula I in the specification. The tetrahydropteridine compound containing the aryl amide or aryl urea structure, disclosed by the invention, has relatively strong inhibitory activity on VEGFR-2 / BRD4 activity; according to the present invention, the VEGFR-2 / BRD4 double-target inhibitor has good anti-proliferative activity on tumor cells, the compound I-5 shows the optimal activity, and the activity is far superior to the positive control Sorafenib, ReGrafenib and JQ-1, the effect of the ReGrafenib and the effect of the combination of the Sorafenib and the JQ-1 respectively, and the target treatment drug for leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like can be prepared, and the compound I-5 can be used for the preparation of the target treatment drug for treating leukemia, gastrointestinal stromal tumor, liver cancer, kidney cancer, thyroid cancer, non-small cell lung cancer, colorectal cancer and the like.

The present invention relates to crystalline avapritinib, polymorphs and hydrates thereof as well as to processes for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising crystalline avapritinib and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of patients with gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM), including aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) and mast cell leukemia (MCL).

This invention relates to the field of medical image artificial intelligence analysis technology, specifically to an automated preoperative precise risk stratification system and method for gastrointestinal stromal tumors. It includes: a data preprocessing module for acquiring the original sequences of multi-phase computed tomography (CT) scans of the patient's abdomen, and performing three-dimensional volume data construction, spatial dimension standardization, and voxel intensity normalization to generate a standardized three-dimensional tensor; a deep learning model module for receiving the three-dimensional tensor and, based on a 3D Swin Transformer architecture, outputting classification probabilities corresponding to four risk levels: very low risk, low risk, intermediate risk, and high risk; and an interpretable visualization module for generating heatmaps identifying key decision-making regions of the model using gradient-weighted class activation mapping technology, and overlaying these heatmaps back onto the original CT images for visualization.

The invention discloses a library construction method for detecting gastrointestinal stromal tumor molecular typing and a gastrointestinal stromal tumor molecular typing method, and belongs to the technical field of biology. Comprising the following steps: fragmenting a DNA (Deoxyribonucleic Acid) extract of a gastrointestinal stromal tumor patient specimen, modifying a terminal, connecting a joint, purifying and pre-amplifying, and carrying out hybridization reaction on a hybridization capture enrichment probe and a pre-amplified sequence to enrich a target sequence; the hybridization capture enrichment probe comprises a sequence as shown in SEQ ID NO: 1-109; the method comprises the following steps of: performing amplification after non-specific capture and binding DNA fragments are eluted and removed, performing nucleic acid concentration and fragment length quantification on a product to obtain a library, and performing bioinformatics analysis on gastrointestinal stromal tumor patient specimen data by next-generation sequencing to obtain gastrointestinal stromal tumor molecular typing information. According to the invention, in-vitro non-diagnostic gastrointestinal stromal tumor molecular typing joint detection is realized, multi-gene variation form identification is completed in one experiment, the detection cost is saved, and the sensitivity is high.

The invention belongs to the technical field of biological medicines, and particularly relates to application of gambogic acid combined with imatinib in preparation of a medicine for treating gastrointestinal stromal tumor. The gambogic acid and the imatinib are jointly applied to treatment of the gastrointestinal stromal tumor, and compared with an existing single imatinib treatment scheme, the gambogic acid and the imatinib can form a synergistic anti-tumor effect, so that the sensitivity of gastrointestinal stromal tumor cells to the imatinib is effectively improved, the problem that the drug effect is insufficient possibly existing when a single drug is used is solved, and the curative effect of the gastrointestinal stromal tumor is improved. And the overall treatment effect is improved. The gambogic acid and imatinib are combined to further inhibit the activity and proliferation of gastrointestinal stromal tumor cells and induce tumor cell apoptosis, so that the gastrointestinal stromal tumor resisting effect is enhanced. Therefore, the invention provides a new strategy and choice for the drug treatment of gastrointestinal stromal tumor, and has important clinical application value.

The invention discloses a novel 4-methyl benzamide compound containing a benzenesulfonyl structure and application thereof, and belongs to the technical field of medicines, the 4-methyl benzamide compound containing the benzenesulfonyl structure has a structure shown in a general formula (I), and can be used for pharmaceutical salt formation by adding acid. Pharmacological activity screening results show that the compound has a remarkable inhibition effect on a human chronic myelogenous leukemia cell strain K562, a human chronic myelogenous leukemia cell imatinib-resistant cell strain K562 / G01, a human gastrointestinal stromal tumor cell strain GIST882 and a human gastrointestinal stromal tumor cell imatinib-resistant cell strain GIST1210, and has a good prospect in development and application of antitumor drugs.

Disclosed are compounds, methods, compositions, and kits that allow for treating cancer by, e.g., targeting cancer stem cells. In some embodiments, the cancer is colorectal cancer, gastric cancer, gastrointestinal stromal tumor, ovarian cancer, lung cancer, breast cancer, pancreatic cancer, prostate cancer, testicular cancer, or lymphoma. In some embodiments, the cancer is liver cancer, endometrial cancer, leukemia, or multiple myeloma. The compounds utilized in the disclosure are of Formula (0), (O′), and (I):

The present invention relates to the use of a 2,3,5-substituted thiophene compound for the prevention, amelioration or treatment of gastrointestinal stromal tumor. The 2,3,5-substituted thiophene compound exhibits high inhibitory activity against the growth of gastrointestinal stromal tumor, and thus may be effectively used for the prevention, amelioration or treatment of gastrointestinal stromal tumor.

The present disclosure provides compounds of Formula (I-0), pharmaceutically acceptable salts thereof, and / or solvates of any of the foregoing, for use in the treatment of diseases and disorders associated with mutant KIT and PDGFRa, and exhibit advantageous non-brain penetration properties for the treatment of diseases and disorders associated with mutant KIT and PDGFRa. The present disclosure also provides methods for the treatment of gastrointestinal stromal tumors and systemic mastocytosis.